Kairos Pharma Ltd (NYSE American: KAPA) is a clinical-stage biopharmaceutical company developing oncology and immunology drug candidates through licensed patented technologies. The company generates no product revenue, funding operations through equity and debt financings rather than commercial sales. Kairos was originally incorporated in California on June 17, 2013 as NanoGB13, Inc., renamed Kairos Pharma Ltd in July 2016, and completed its IPO on NYSE American on September 17, 2024. Its pipeline includes ENV 105, in Phase 1 and Phase 2 clinical trials, and KROS 201, in a Phase 1 trial, as of the fiscal year ended December 31, 2024. Core technologies are licensed from Cedars-Sinai Medical Center under exclusive license agreements. Dr. Ramachandran Murali, Vice President of Research and Development and a physician-scientist at Cedars-Sinai, is an inventor of three of the patented technologies underlying those licenses. Operating expenses consist entirely of research and development costs and general and administrative expenses.

Revenue model

Pre-revenue clinical-stage company. No product sales as of fiscal year ended December 31, 2024. Operations funded through equity and debt financings, including an IPO completed September 17, 2024.

Products and services

ENV 105: Phase 1 and Phase 2 clinical trials ongoing as of FY2024. KROS 201: Phase 1 clinical trial ongoing as of FY2024. Preclinical research includes animal disease models, medicinal chemistry, formulation, and toxicology and biodistribution studies.

Customers and end markets

No commercial customers as of FY2024. End market is oncology and immunology therapeutics, contingent on successful clinical development and regulatory approval.

Value-chain role

Drug developer and clinical-stage sponsor. Relies on third-party contract research organizations and clinical investigators for trial execution while retaining regulatory responsibility for protocol compliance, GCP adherence, and GLP standards.

Geographic exposure

Incorporated in Delaware. Listed on NYSE American. Technologies licensed from Cedars-Sinai Medical Center. No disclosed international commercial operations as of FY2024.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations